TRAF3IP2 (rs13190932) polymorphism in psoriasis and psoriatic arthritis: susceptibility, systemic inflammation and response to methotrexate.

INTRODUCTION: Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated inflammatory disorders. The TRAF3IP2 gene encodes Act1, a crucial adaptor protein in interleukin-17 signalling, which is fundamental to the pathophysiology of psoriasis and psoriatic arthritis. AIM: To examine the correlation between the TRAF3IP2 (rs13190932) polymorphism and the susceptibility to psoriasis and PsA. MATERIAL AND METHODS: This prospective observational cohort study enrolled 120 patients with psoriasis, comprising 40 with PsA, alongside 40 age- and sex-matched healthy controls. The Psoriasis Area and Severity Index (PASI) and the Disease Activity Index for Psoriatic Arthritis (DAPSA) were used. Real-time polymerase chain reaction was used to genotype TRAF3IP2 (rs13190932). We used non-parametric statistical analyses. RESULTS: Patients with psoriasis showed markedly elevated inflammatory markers and metabolic irregularities in comparison to controls. The AA genotype and A allele of TRAF3IP2 (rs13190932) were substantially more prevalent in patients with psoriasis and psoriatic arthritis, indicating heightened disease vulnerability. There was a positive correlation between disease severity and systemic inflammatory markers. After 12 weeks of treatment with methotrexate, the PASI and DAPSA scores significantly decreased. There was no notable correlation between TRAF3IP2 genotypes and illness severity or therapy response. CONCLUSIONS: The TRAF3IP2 (rs13190932) polymorphism is substantially linked to susceptibility to psoriasis and psoriatic arthritis, but not to disease severity or short-term response to methotrexate. Methotrexate continues to be an effective short-term systemic treatment for both diseases.